Mouse Tumor Necrosis Factor Alpha" by TK Vallery - Own work. Licensed under CC BY-SA 3.0 via Wikimedia Commons

The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.

Ali Borazan, Hasan Ustün, Yucel Ustundag, Selim Aydemir, Taner Bayraktaroglu, Mehmet Sert, and Ahmet Yilmaz


BACKGROUND

Markers of an acute phase reaction, such as C-reactive protein (CRP) or tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6, are predictive for cardiovascular morbidity and mortality in normal subjects and in chronic renal failure patients. In this study, we aimed to investigate serum TNF-alpha, IL-6, IL-10 and CRP levels in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients.

MATERIALS AND METHODS

Serum levels of TNF-alpha, IL-6, IL-10 and CRP levels were measured in 30 patients who were just diagnosed with end-stage renal failure and treated, with 16 CAPD (nine female, seven male) and 14 HD (eight female, six male) patients, before CAPD or HD treatment and after 3 months from the beginning of CAPD or HD in patients with no clinical signs of infection. The control groups were 20 healthy persons of similar age and sex. Serum levels of TNF-alpha, IL-6, IL-10 and CRP were measured by enzyme-linked immunosorbent assay in stable CAPD and HD patients and in healthy persons.

RESULTS

The mean serum levels of TNF-alpha, IL-6, IL-10 and CRP showed no significant differences between the CAPD and HD patients for the beginning values and the third month of treatment. However, serum TNF-alpha, IL-6, IL-10 and CRP levels were higher than the control group in the CAPD and HD patients regarding the beginning values and the third month of treatment (p < 0.001). CONCLUSIONS: CAPD and HD of the renal replacement therapy have no effects on serum CRP and cytokines.

Selected References

  • Eikelboom JW, Hankey GJ. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens. 2001 May;10(3):377–383. [PubMed]
  • Stompór Tomasz, Pasowicz Mieczyslsław, Sulłowicz Władysław, Dembińska-Kieć Aldona, Janda Katarzyna, Wójcik Katarzyna, Tracz Wiesława, Zdzienicka Anna, Klimeczek Piotr, Janusz-Grzybowska Eve. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis. 2003 Jan;41(1):203–211. [PubMed]
  • Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, Camm AJ, Northfield TC. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997 Sep;78(3):273–277.[PMC free article] [PubMed]
  • Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol.1993;11:767–804. [PubMed]
  • Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients.Nephron. 1998 Aug;79(4):399–407. [PubMed]
  • Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001 Jun;16(6):1189–1197. [PubMed]
  • Boenisch Olaf, Ehmke Klaus-Dieter, Heddergott Adalbert, Naoum Claudia, Frei Ulrich, Schindler Ralf. C-reactive-protein and cytokine plasma levels in hemodialysis patients. J Nephrol. 2002 Sep-Oct;15(5):547–551. [PubMed]
  • Docci D, Bilancioni R, Buscaroli A, Baldrati L, Capponcini C, Mengozzi S, Turci F, Feletti C. Elevated serum levels of C-reactive protein in hemodialysis patients. Nephron. 1990;56(4):364–367. [PubMed]
  • Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int.1999 Feb;55(2):648–658. [PubMed]
  • Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998 Aug;54(2):627–636.[PubMed]
  • Dikow Ralf, Adamczak Marcin, Henriquez Daniel Ernesto, Ritz Eberhard. Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl. 2002 May;(80):5–10. [PubMed]
  • Bayés Beatriu, Pastor M Cruz, Bonal Jordi, Juncà Jordi, Hernandez José M, Riutort Nadal, Foraster Andreu, Romero Ramón. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant. 2003 Jan;18(1):106–112. [PubMed]
  • Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997 Feb 15;349(9050):462–466. [PubMed]
  • Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997 Jan;43(1):52–58. [PubMed]